Juan Jose Perez-Ruixo
Clinical Pharmacology Division
Johnson & Johnson Pharmaceutical Research & Development
Beerse
Belgium
Name/email consistency: high
- Exposure-toxicity relationships for tipifarnib in cancer patients. Perez-Ruixo, J.J., Chen, W., Zhang, S., Hayes, S., Chow, A. Br. J. Clin. Pharmacol (2007)
- Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. Perez-Ruixo, J.J., Zannikos, P., Ozdemir, V., Franc, M.A., Francke, S., Piotrovsky, V. Cancer Chemother. Pharmacol. (2006)
- Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Perez-Ruixo, J.J., Piotrovskij, V., Zhang, S., Hayes, S., De Porre, P., Zannikos, P. Br. J. Clin. Pharmacol (2006)
- Population cell life span models for effects of drugs following indirect mechanisms of action. Perez-Ruixo, J.J., Kimko, H.C., Chow, A.T., Piotrovsky, V., Krzyzanski, W., Jusko, W.J. J. Pharmacokinet. Pharmacodyn (2005)